Related Experiment Video

Updated: Jul 6, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor

Shipra Malik1, Sai Pallavi Pradeep1, Vikas Kumar1

  • 1Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA.

Cell Reports. Medicine
|January 6, 2024
PubMed

Insights

Scientists developed a novel gamma peptide nucleic acid (γPNA) platform to target oncogenes directly in genomic DNA. This breakthrough enables in vivo silencing of cancer-driving genes, offering new precision medicine strategies.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Therapeutics

Background:

  • Targeting oncogenes is crucial for precision cancer medicine.
  • Current strategies focus on RNA and protein, with limited success in targeting genomic DNA.
  • Direct genomic DNA targeting offers a new therapeutic frontier.

Purpose of the Study:

  • To introduce and validate a gamma peptide nucleic acid (γPNA)-based platform for targeting genomic DNA.
  • To evaluate the efficacy and safety of this platform for oncogene silencing in vivo.
  • To explore combination therapies for enhanced antitumor activity.

Main Methods:

  • Development of γPNA molecules for specific genomic DNA binding.
  • In vitro validation of γPNA-mediated inhibition of c-Myc transcription.
  • In vivo assessment of γPNA efficacy and safety in preclinical cancer models.
  • Evaluation of combination therapies with histone deacetylase inhibitors and chemotherapy.

Main Results:

  • γPNAs demonstrated high affinity and specificity for invading genomic DNA.
  • Established proof-of-concept for inhibiting c-Myc transcription using γPNA.
  • Demonstrated in vivo efficacy and safety in preclinical models.
  • Combination therapy with γPNA showed robust antitumor activity in xenografts.

Conclusions:

  • γPNA represents a viable platform for direct genomic DNA targeting to silence oncogenes.
  • This approach offers a novel strategy for cancer therapy and precision medicine.
  • Combination therapies enhance the therapeutic potential of genomic DNA-targeted agents.
Keywords:
HDACiPNAc-Myccancer therapychemotherapyhistone deacetylase inhibitorslymphomanuclear deliverypeptide nucleic acidtranscription inhibition

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529